Glucocerebrosidase (GBA1) variants have been documented as the most significant genetic risk for Parkinson’s disease (PD) globally.1GBA1-associated PD has an earlier age of disease onset, faster motor progression and more frequent non-motor symptoms specifically cognitive decline/dementia, visual hallucinations, hyposmia, autonomic features and rapid eye movement (REM) sleep behavior disorder (RBD). The gene discussed is GBA1; the disease is dementia.